Leqvio and Hair loss - a phase IV clinical study of FDA data

Summary:

Hair loss is reported as a side effect among people who take Leqvio (inclisiran sodium), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Aspirin, and have High blood cholesterol.

The phase IV clinical study analyzes which people have Hair loss when taking Leqvio. It is created by eHealthMe based on reports of 4,049 people who have side effects when taking Leqvio from the FDA, and is updated regularly.

What is Leqvio?

Leqvio has active ingredients of inclisiran sodium. eHealthMe is studying from 4,052 Leqvio users. Check the latest studies of Leqvio.

What is Hair loss?

Hair loss is found to be associated with 2,411 drugs and 3,513 conditions by eHealthMe. Check the latest studies of Hair loss.

On Jul, 21, 2026

4,049 people reported to have side effects when taking Leqvio.
Among them, 36 people (0.89%) have Hair loss.

Among these 36 people:

How long have people been on Leqvio when they have Hair loss? *

What is the gender of people who have Hair loss when taking Leqvio? *

female: 97.22 %
male: 2.78 %

What is the age of people who have Hair loss when taking Leqvio? *

What are other drugs people take besides Leqvio? *

What are other side effects people have besides Hair loss? *

Joint Pain: 8 people, 22.22%
Chest Pain: 4 people, 11.11%
Muscle Aches (muscle pain): 4 people, 11.11%
Heart Palpitations (feelings or sensations that your heart is pounding or racing): 4 people, 11.11%
Drug Ineffective: 3 people, 8.33%
Fibromyalgia (a long-term condition which causes pain all over the body): 3 people, 8.33%
The Flu (the flu is caused by an influenza virus): 3 people, 8.33%
General Physical Health Deterioration (weak health status): 3 people, 8.33%
Immunosuppressant Drug Level Increased: 3 people, 8.33%
Injection Site Pain: 3 people, 8.33%

What are the existing conditions these people have? *

High Blood Cholesterol: 6 people, 16.67%
Atherosclerosis (disorder of the arteries): 5 people, 13.89%
Low Density Lipoprotein Increased (cholesterol increased in blood): 2 people, 5.56%
Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 5.56%
Diabetes: 2 people, 5.56%
Blood Pressure Abnormal: 2 people, 5.56%
Low Density Lipoprotein: 1 person, 2.78%
Joint Pain: 1 person, 2.78%
High Density Lipoprotein Increased: 1 person, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Leqvio and have Hair loss?

- Check whether Hair loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Leqvio:

Leqvio (4,052 reports)

Hair loss treatments and more:

Hair loss (271,201 reports)

Browse all side effects of Leqvio:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hair loss:

Hair loss (2,411 drugs)

Browse all the conditions that are associated with Hair loss:

Hair loss (3,513 conditions)

Related publications that referenced our studies

Lindsey SF, Tosti A, "Hair loss induced by tumor necrosis factor alpha inhibitors", J Clin Investigat Dermatol, 2015 Jan .
Lindsey SF, Tosti A, "Hair loss induced by tumor necrosis factor alpha inhibitors", J Clin Investigat Dermatol, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on inclisiran sodium (the active ingredients of Leqvio) and Leqvio (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.